Search details
1.
A Neutrophil Timer Coordinates Immune Defense and Vascular Protection.
Immunity
; 50(2): 390-402.e10, 2019 02 19.
Article
in English
| MEDLINE | ID: mdl-30709741
2.
Novel Germline TET2 Mutations in Two Unrelated Patients with Autoimmune Lymphoproliferative Syndrome-Like Phenotype and Hematologic Malignancy.
J Clin Immunol
; 43(1): 165-180, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36066697
3.
Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.
Hematol Oncol
; 41(5): 869-876, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37545392
4.
A Neutrophil Timer Coordinates Immune Defense and Vascular Protection.
Immunity
; 51(5): 966-967, 2019 Nov 19.
Article
in English
| MEDLINE | ID: mdl-31747583
5.
Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID-19 patients.
Eur J Immunol
; 51(3): 634-647, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33251605
6.
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
Cancer Immunol Immunother
; 71(3): 627-636, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34297159
7.
Relevant SARS-CoV-2 viremia is associated with COVID-19 severity: Prospective cohort study and validation cohort.
J Med Virol
; 94(11): 5260-5270, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35811284
8.
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
J Allergy Clin Immunol
; 147(1): 72-80.e8, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33010257
9.
Retrospective comparison between COBE SPECTRA and SPECTRA OPTIA apheresis systems for hematopoietic progenitor cells collection for autologous and allogeneic transplantation in a single center.
J Clin Apher
; 35(5): 453-459, 2020 Sep.
Article
in English
| MEDLINE | ID: mdl-32798328
10.
Rituximab induces a lasting, non-cumulative remodelling of the B-cell compartment.
Clin Exp Rheumatol
; 37(4): 615-622, 2019.
Article
in English
| MEDLINE | ID: mdl-30620289
11.
Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain: RITAR Study.
J Clin Rheumatol
; 25(6): 258-263, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-30001257
12.
Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
Ther Drug Monit
; 39(3): 252-262, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28490048
13.
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia.
Cancer Immunol Immunother
; 64(6): 665-76, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25724841
14.
NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins.
Nat Commun
; 15(1): 2100, 2024 Mar 07.
Article
in English
| MEDLINE | ID: mdl-38453949
15.
Erythroid SLC7A5/SLC3A2 amino acid carrier controls red blood cell size and maturation.
iScience
; 26(1): 105739, 2023 Jan 20.
Article
in English
| MEDLINE | ID: mdl-36582828
16.
Dasatinib-induced spleen contraction leads to transient lymphocytosis.
Blood Adv
; 7(11): 2418-2430, 2023 06 13.
Article
in English
| MEDLINE | ID: mdl-36583674
17.
Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis.
Front Med (Lausanne)
; 10: 1215246, 2023.
Article
in English
| MEDLINE | ID: mdl-37809329
18.
Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients.
Cancers (Basel)
; 14(11)2022 May 31.
Article
in English
| MEDLINE | ID: mdl-35681706
19.
Monitoring and safety of CAR-T therapy in clinical practice.
Expert Opin Drug Saf
; 21(3): 363-371, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34519234
20.
Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9+ tumors.
Front Immunol
; 13: 825635, 2022.
Article
in English
| MEDLINE | ID: mdl-35967322